TABLE 6.
A summary of current clinical trials for erosolized exosomes.
| NP | APIs | Target disease | Phase | Status | Sponsor | Identifier |
|---|---|---|---|---|---|---|
| CSTC-derived exosomes | N/A | Coronavirus + pneumonia | I | Active | TC ericyes university | NCT04389385 |
| MPC-derived exosomes | N/A | Drug resistance | I/II | Recruiting | Ruijin hospital | NCT04544215 |
| MSC-derived exosomes | N/A | Coronavirus | I | Completed in 2020 | Ruijin hospital | NCT04276987 |
| MSC-derived exosomes | N/A | Healthy tolerance | I | Recruiting | Ruijin hospital | NCT04313647 |
| MSC-derived exosomes | N/A | ARDS | I/II | Not yet recruiting | Ruijin hospital | NCT04602104 |
CSTC, COVID-19 specific T cell; MPC, mesenchymal stem/progenitor cell; MSC, mesenchymal stem cell; ARDS, acute respiratory distress syndrome.